An Insightful Overview of Atrial Fibrillation Surgery Market

An Insightful Overview of Atrial Fibrillation Surgery Market

The market for Atrial Fibrillation Surgery is widely growing due to the rising number of Atrial Fibrillation Surgery cases mostly caused due to lifestyle and genetics like hypertension, obesity, diabetes and so on.

It is gaining importance not only among the aged population but also among the young adults. The growing focus on catheter ablation procedures driven by technology has propelled the Atrial Fibrillation Surgery market.

Atrial Fibrillation is a condition where the heart beats irregularly unlike the normal heart. The top chambers or the atria quiver in a very fast pace and so the blood flow slows down. Ventricles or the main pumping chambers also do not push the blood around efficiently. If left untreated, atrial fibrillation increases the risk of heart attacks and strokes.

There are four different types of Atrial Fibrillation.

Paroxysmal Atrial Fibrillation is that type of Atrial Fibrillation begins and ends suddenly. Heartbeat is irregular and may last anywhere from seconds to weeks. Most episodes of Paroxysmal Atrial Fibrillation resolve themselves.

Persistent Atrial Fibrillation is a condition that may last even a week and may not end on its own. It may require medical intervention like cardioversion wherein the doctor applies shock to your heart to stop an acute, persistent Atrial Fibrillation episode.

Long-Standing Persistent Atrial Fibrillation is a condition that may last even up to a year without interruption. This eventually causes structural heart damage. This type of condition may not respond to regular treatment. It may involve invasive surgical procedures like electro cardioversion, catheter ablation, pacemaker implantation and so on.

Permanent Atrial Fibrillation is a long-standing condition that can become permanent and treatment does not restore normal heart rate. This means your heart is in the state of Atrial Fibrillation all the time. As per research, this condition results in lower quality of life and increased risk of a cardiac arrest.

Treatment for general Atrial Fibrillation includes rhythm control, heart rate control, and prevention of heart failure. But in advanced cases, surgical procedures may be necessary to destroy the heart tissue where there are erratic signals and restore the heart to its normalcy. For this procedure, either catheter or open heart surgery works.

The market worth of Global Atrial Fibrillation Surgery market was 1.02 billion US Dollars in 2016 and is expected to grow at a CAGR of 14% and reach USD 1.98 billion by 2021.

While developed nations will continue to dominate the market in terms of revenue, developing nations also are responding to the market optimistically because of the improved health infrastructure and increase in ablation centers. There has also been a rising focus on healthcare amongst the middle-class population.  Competitive treatment costs and good reimbursement policies are also expected to drive the market.

The Atrial Fibrillation Surgery Market is categorized on the basis of surgical procedure, product, and region. Based on the procedure, the market is categorized into Catheter Ablation Procedure and Surgical Ablation Procedure or Maze Procedure. On the basis of the product, there are two categories- Catheter Ablation and Surgical Ablation.

Catheter Ablation surgical devices are anticipated to be the fastest growing segment because of its high use and acceptance in surgical procedures.

Geographically, the market is spread over North America, Europe, Latin-America and Asia Pacific and the Middle East. Due to the availability of advanced healthcare facilities, North America leads the Atrial Fibrillation Surgery market. Following closely is the Asia Pacific market because of the huge number of population with a high risk of heart disease.

Few of the main players here are Boston Scientific Corporation, St. Jude Medical Inc., Biosense Webster, Inc., Medtronic, Inc., Articure Inc., Cardima Inc. nContact Inc., Biotronik SE & Co and Cardiofocus Inc.

 
This press release has been viewed 47 times on PR Buzz.